Myriad raises price of BRCA testing, again.

On April 1, 2010 - three days after a court ruling that invalidated Myriad's patents on the BRCA1 and BRCA2 genes (associated with hereditary breast and ovarian cancer) the company increased their prices for genetic testing. Old cost =$3,770. New cost = $4,040 for full sequencing plus rearrangement testing.